Prediction of response to preoperative chemoradiotherapy and establishment of individualized therapy in advanced rectal cancer

Nakao,Toshihiro; Iwata,Takashi; Hotchi,Masanori; Yoshikawa,Kozo; Higashijima,Jun; Nishi,Masaaki; Takasu,Chie; Eto,Shohei; Teraoku,Hiroki; Shimada,Mitsuo

doi:10.3892/or.2015.4196

Prediction of response to preoperative chemoradiotherapy and establishment of individualized therapy in advanced rectal cancer

Authors:
- Toshihiro Nakao
- Takashi Iwata
- Masanori Hotchi
- Kozo Yoshikawa
- Jun Higashijima
- Masaaki Nishi
- Chie Takasu
- Shohei Eto
- Hiroki Teraoku
- Mitsuo Shimada
View Affiliations

Affiliations: Department of Surgery, Tokushima University, Tokushima 770-8503, Japan
Published online on: August 10, 2015 https://doi.org/10.3892/or.2015.4196
Pages: 1961-1967

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Preoperative chemoradiotherapy (CRT) has become the standard treatment for patients with locally advanced rectal cancer. However, no specific biomarker has been identified to predict a response to preoperative CRT. The aim of the present study was to assess the gene expression patterns of patients with advanced rectal cancer to predict their responses to preoperative CRT. Fifty-nine rectal cancer patients were subjected to preoperative CRT. Patients were randomly assigned to receive CRT with tegafur/gimeracil/oteracil (S-1 group, n=30) or tegafur-uracil (UFT group, n=29). Gene expression changes were studied with cDNA and miRNA microarray. The association between gene expression and response to CRT was evaluated. cDNA microarray showed that 184 genes were significantly differentially expressed between the responders and the non‑responders in the S-1 group. Comparatively, 193 genes were significantly differentially expressed in the responders in the UFT group. TBX18 upregulation was common to both groups whereas BTNL8, LOC375010, ADH1B, HRASLS2, LOC284232, GCNT3 and ALDH1A2 were significantly differentially lower in both groups when compared with the non-responders. Using miRNA microarray, we found that 7 and 16 genes were significantly differentially expressed between the responders and non-responders in the S-1 and UFT groups, respectively. miR-223 was significantly higher in the responders in the S-1 group and tended to be higher in the responders in the UFT group. The present study identified several genes likely to be useful for establishing individualized therapies for patients with rectal cancer.

View Figures

View References

1	Sauer R: Adjuvant and neoadjuvant radiotherapy and concurrent radiochemotherapy for rectal cancer. Pathol Oncol Res. 8:7–17. 2002. View Article : Google Scholar : PubMed/NCBI
2	Gérard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, et al: Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: Results of FFCD 9203. J Clin Oncol. 24:4620–4625. 2006. View Article : Google Scholar : PubMed/NCBI
3	Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A and Ollier JC; EORTC Radiotherapy group Trial 22921: Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 355:1114–1123. 2006. View Article : Google Scholar : PubMed/NCBI
4	Morimoto S, Shimada M, Kurita N, Sato H, Iwata T, Nishioka M, Yoshikawa K, Miyatani T, Kashihara H, Takasu C, et al: Preoperative radiotherapy combined with S-1 for advanced lower rectal cancer: Phase I trial. Hepatogastroenterology. 59:1428–1432. 2012.
5	Hotchi M, Okitsu H, Miura M, et al: A phase II trial of preoperative chemoradiotherapy with oral DPD-inhibitory fluoropyrimimidines in patients with advanced rectal cancer. J Cancer Ther. 3:989–995. 2012. View Article : Google Scholar
6	Ghadimi BM, Grade M, Difilippantonio MJ, Varma S, Simon R, Montagna C, Füzesi L, Langer C, Becker H, Liersch T, et al: Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol. 23:1826–1838. 2005. View Article : Google Scholar : PubMed/NCBI
7	Kim IJ, Lim SB, Kang HC, Chang HJ, Ahn SA, Park HW, Jang SG, Park JH, Kim DY, Jung KH, et al: Microarray gene expression profiling for predicting complete response to preoperative chemoradiotherapy in patients with advanced rectal cancer. Dis Colon Rectum. 50:1342–1353. 2007. View Article : Google Scholar : PubMed/NCBI
8	Rimkus C, Friederichs J, Boulesteix AL, Theisen J, Mages J, Becker K, Nekarda H, Rosenberg R, Janssen KP and Siewert JR: Microarray-based prediction of tumor response to neoadjuvant radiochemotherapy of patients with locally advanced rectal cancer. Clin Gastroenterol Hepatol. 6:53–61. 2008. View Article : Google Scholar : PubMed/NCBI
9	Watanabe T, Kobunai T, Akiyoshi T, Matsuda K, Ishihara S and Nozawa K: Prediction of response to preoperative chemoradiotherapy in rectal cancer by using reverse transcriptase polymerase chain reaction analysis of four genes. Dis Colon Rectum. 57:23–31. 2014. View Article : Google Scholar
10	Pazdur R, Hoff PM, Medgyesy D, Royce M and Brito R: The oral fluorouracil prodrugs. Oncology. 12(Suppl 7): S48–S51. 1998.
11	Giralt J, Tabernero J, Navalpotro B, Capdevila J, Espin E, Casado E, Mañes A, Landolfi S, Sanchez-Garcia JL, de Torres I, et al: Pre-operative chemoradiotherapy with UFT and Leucovorin in patients with advanced rectal cancer: A phase II study. Radiother Oncol. 89:263–269. 2008. View Article : Google Scholar : PubMed/NCBI
12	Van Cutsem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, Graeven U, Lokich J, Madajewicz S, Maroun JA, et al: Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: Integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer. 90:1190–1197. 2004. View Article : Google Scholar : PubMed/NCBI
13	Lee EM, Hong YS, Kim KP, Lee JL, Kim SY, Park YS, Choi DH, Kim JH, Lim SB, Yu CS, et al: Phase II study of preoperative chemoradiation with S-1 plus oxaliplatin in patients with locally advanced rectal cancer. Cancer Sci. 104:111–115. 2013. View Article : Google Scholar
14	Saigusa S, Toiyama Y, Tanaka K, Yokoe T, Okugawa Y, Kawamoto A, Yasuda H, Inoue Y, Miki C and Kusunoki M: Stromal CXCR4 and CXCL12 expression is associated with distant recurrence and poor prognosis in rectal cancer after chemoradiotherapy. Ann Surg Oncol. 17:2051–2058. 2010. View Article : Google Scholar : PubMed/NCBI
15	Zhang J, Luo X, Li H, Yue X, Deng L, Cui Y and Lu Y: MicroRNA-223 functions as an oncogene in human colorectal cancer cells. Oncol Rep. 32:115–120. 2014.PubMed/NCBI
16	Li X, Zhang Y, Zhang H, Liu X, Gong T, Li M, Sun L, Ji G, Shi Y, Han Z, et al: miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3. Mol Cancer Res. 9:824–833. 2011. View Article : Google Scholar : PubMed/NCBI
17	Kurashige J, Watanabe M, Iwatsuki M, Kinoshita K, Saito S, Hiyoshi Y, Kamohara H, Baba Y, Mimori K and Baba H: Overexpression of microRNA-223 regulates the ubiquitin ligase FBXW7 in oesophageal squamous cell carcinoma. Br J Cancer. 106:182–188. 2012. View Article : Google Scholar :
18	Pinatel EM, Orso F, Penna E, Cimino D, Elia AR, Circosta P, Dentelli P, Brizzi MF, Provero P and Taverna D: miR-223 is a coordinator of breast cancer progression as revealed by bioinformatics predictions. PLoS One. 9:e848592014. View Article : Google Scholar : PubMed/NCBI
19	Liang L, Zhu J, Zaorsky NG, Deng Y, Wu X, Liu Y, Liu F, Cai G, Gu W, Shen L, et al: MicroRNA-223 enhances radiation sensitivity of U87MG cells in vitro and in vivo by targeting ataxia telangiectasia mutated. Int J Radiat Oncol Biol Phys. 88:955–960. 2014. View Article : Google Scholar : PubMed/NCBI
20	Hotchi M, Shimada M, Kurita N, Iwata T, Sato H, Morimoto S, Yoshikawa K, Higashijima J and Miyatani T: microRNA expression is able to predict response to chemoradiotherapy in rectal cancer. Mol Clin Oncol. 1:137–142. 2013.PubMed/NCBI